Vadastuximab tedelpar antibody-drug conjugate representing a crucial advancement in the treatment of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a protein frequently expressed https://bookmarklinking.com/story11063737/vadastuximab-a-deep-examination-into-cd33-targeted-therapy